Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Melanie Sue Joy

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-DOPS General Operations
Phone303/724-7416

    Collapse Research 
    Collapse research activities and funding
    R41DK139916     (JOY, MELANIE S)Jun 20, 2025 - May 31, 2026
    NIH
    Novel Extracorporeal Technology for Kidney Disease
    Role: Principal Investigator
    R21AR082655     (JOY, MELANIE S)Sep 22, 2023 - Sep 14, 2025
    NIH
    Diversification of Glomerular Kidney Disease Treatments By Targeting Therapeutics to the Kidney
    Role: Principal Investigator
    R01CA277313     (JOY, MELANIE S)Jul 7, 2023 - Jun 30, 2028
    NIH
    Preclinical and Clinical Models of Drug Induced Kidney Injury
    Role: Principal Investigator
    R01GM123330     (ALEKSUNES, LAUREN M)Sep 15, 2018 - Jul 31, 2022
    NIH
    Drug Disposition and Nephrotoxicity
    Role: Co-Principal Investigator
    R01GM107122     (JOY, MELANIE S)Sep 15, 2014 - Aug 31, 2020
    NIH
    Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease
    Role: Principal Investigator
    R21DK093903     (JOY, MELANIE S)Sep 21, 2012 - Jun 30, 2015
    NIH
    Pharmacokinetic and Pharmacogenomic Determinants of Cisplatin Kidney Injury
    Role: Principal Investigator
    K23DK064888     (JOY, MELANIE S)Sep 1, 2004 - Aug 31, 2010
    NIH
    Pharmacokinetics &Genomics in Glomerular Diseases
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Thompson LE, Ghimire A, Wen X, Kim C, Doherty CL, Buckley BT, Bowles DW, O'Bryant CL, Jaimes EA, Aleksunes LM, Joy MS. Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs. J Clin Pharmacol. 2025 Jun; 65(6):763-778. PMID: 39711135.
      View in: PubMed
    2. Thompson LE, Joy MS. Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury. J Pharmacol Exp Ther. 2024 Nov 19; 391(3):399-414. PMID: 39322416.
      View in: PubMed
    3. Thompson LE, Ghimire A, Wen X, Kim C, Choza J, Doherty CL, Buckley BT, Bowles DW, O'Bryant CL, Pfister DG, Jaimes EA, Aleksunes LM, Joy MS. A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule-1 Biomarker. J Pharmacol Clin Toxicol. 2024; 12(1). PMID: 39726772.
      View in: PubMed
    4. Thompson LE, Joy MS. Endogenous markers of kidney function and renal drug clearance processes of filtration, secretion, and reabsorption. Curr Opin Toxicol. 2022 Sep; 31. PMID: 36777447.
      View in: PubMed
    5. Villegas LR, Rivard CJ, Hunter B, You Z, Roncal C, Joy MS, Le MT. Effects of fructose-containing sweeteners on fructose intestinal, hepatic, and oral bioavailability in dual-catheterized rats. PLoS One. 2018; 13(11):e0207024. PMID: 30408104.
      View in: PubMed
    6. Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2019 Jan; 75(1):51-57. PMID: 30220072.
      View in: PubMed
    7. Gist KM, Cooper DS, Wrona J, Faubel S, Altmann C, Gao Z, Marino BS, Alten J, Hock KM, Mizuno T, Vinks AA, Joy MS, Wempe MF, Bennett MR, Goldstein SL. Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac Surgery. Ther Drug Monit. 2018 04; 40(2):186-194. PMID: 29529007.
      View in: PubMed
    8. Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017 Jun 22; 18(7). PMID: 28640195.
      View in: PubMed
    9. Gist KM, Goldstein SL, Joy MS, Vinks AA. Milrinone Dosing Issues in Critically Ill Children With Kidney Injury: A Review. J Cardiovasc Pharmacol. 2016 Feb; 67(2):175-81. PMID: 26448275.
      View in: PubMed
    10. Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H. Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS One. 2015; 10(9):e0136558. PMID: 26335102.
      View in: PubMed
    11. Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015 Apr; 43(4):611-9. PMID: 25650382.
      View in: PubMed
    Joy's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (70) concept(s)
    _
    Co-Authors Expand Description
    See all (10) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)